> ## Content Index
> Fetch the complete content index at: https://www.healthdatacon.io/llms.txt
> Use this file to discover other available public pages before exploring further.

# Enveda urges drug developers to reuse its AI manufacturing-record checker
- URL: https://www.healthdatacon.io/articles/enveda-ai-checker-drug-manufacturing-records-hlth-2026/
- Published: 2026-11-18T18:40:00.000Z
- Updated: 2026-11-19T10:46:16.000Z
- Description: Dan Wee described the Anthropic collaboration and the work that still sits with quality reviewers when software flags an issue in a regulated record.
- Author: HDM Staff
- Tags: AI, Americas, HLTH

Enveda has made available an example of the AI document checker it developed with Anthropic to flag problems in pharmaceutical manufacturing records. Dan Wee, the biotechnology company’s chief execution officer, said Wednesday that the company shared its work because other teams face many of the same labor-intensive document reviews during drug development.

Wee discussed the project at [The CDMO Forum](https://hlth.com/events/usa/agenda/2026/the-cdmo-forum?ref=healthdatacon.io) during HLTH USA 2026 in Las Vegas. The moderator led the discussion. Wee described manufacturing records and regulatory paperwork as work that can consume substantial time and money long after scientists have a promising candidate. “We’ve made that publicly available,” Wee said, pointing attendees to the document checker’s GitHub repository. He said the work targeted paperwork and standard operating procedures, adding that “we found seven major findings in our batch record” that reviewers had missed.

The tool gives reviewers a way to identify possible problems and decide which ones need more investigation. Enveda calls it the CMC Document Processor, a reference to the chemistry, manufacturing and controls portion of drug development. It works from copies of documents. Enveda says its personnel still decide whether a flag is meaningful, how to resolve it and whether a record is ready to use.

## A timed review showed faster detection in one manufacturing record set

Enveda and Anthropic [published an evaluation](https://enveda.com/news/enveda-collaborates-with-anthropic-to-accelerate-drug-development/?ref=healthdatacon.io) on October 27\. Enveda said it checked 1,061 pages of manufacturing records from a Phase 2 campaign. Four internal reviewers and external consultants reviewed the same material, and a quality team member evaluated the findings against what an auditor would be expected to raise. Across multiple runs, the software identified the 11 actionable issues found in the human review.

In one timed run, Enveda said the software flagged seven additional issues its team considered relevant and resolved with the manufacturer. It also misread a handwritten note, which it marked for verification. The company reported that this run took just under three hours including human adjudication, compared with almost 26 hours for its four reviewers. That timing is for one packet and one comparison. Rates of error and review time on records from different sites, products and document formats remain questions for future evaluations.

For a quality team, a flag becomes useful when it can be checked against the original document and when someone is accountable for deciding what happens next. A form may contain a genuine omission. It can also be missing a piece of information that was recorded elsewhere. When that happens, reviewing the context is part of the decision. Wee described the value of giving software the relevant context for the work, rather than asking it to make a judgment from isolated pages.

## The regulated record stays under human control

In [Anthropic’s account](https://www.anthropic.com/research/early-progress-drug-development?ref=healthdatacon.io), the checker received read-only copies of files. Enveda’s validated document management system remained the record of authority. That separation gives reviewers a defined place to check source material, make corrections and record decisions. It also gives a company a clearer way to audit whether the software’s recommendation affected the work.

The companies also described experiments drafting parts of an application to begin clinical testing. Enveda said reviewers corrected a unit-conversion error in an AI-drafted investigator’s brochure before submitting it as part of an application to the Food and Drug Administration. The two examples address different jobs. A checker flags possible discrepancies in existing material, while a drafting system has to preserve facts and units as it turns source evidence into narrative. Each requires a separate review of how errors can enter the work.

## Building the record with patient organizations

The panel also considered how a development team learns what patients need and can realistically do. Jennifer Lannon, vice president of registries and partnerships at Alira Health, described partnering with patient advocacy groups to “run patient registries.” A registry can collect information over time from people with a condition and give investigators another place to look when considering how to design a study or reach potential participants.

Lannon’s employer, a contract research organization, [describes registries](https://alirahealth.com/education-hub/hlth-usa/?ref=healthdatacon.io) as one way to improve how sponsors identify and enroll people in rare disease research. The work depends on what participants are asked to share, which questions the registry is built to answer and how well it reflects people beyond the patients already connected to an advocacy group. Those choices affect whether the resulting record will help a team design a study that people can join.

In a discussion of interactions with regulators, Lannon urged developers to explain the reasoning behind a proposal and show the supporting information. She described room to suggest different approaches “as long as you have evidence” for them. She was offering her view as a research and patient engagement executive. Her remarks were about what a developer can bring to a discussion with the agency, which is a separate question from what the agency ultimately accepts.

Lannon offered an example in which an advocacy group helped a sponsor respond to an impending supply interruption after its contract manufacturer filed for bankruptcy. She said the sponsor explained the expected timing to affected patients and later needed a usability study because the product combined a drug and a device. “They filled that usability study in like a week,” she said. Lannon did not name the product or sponsor. The example showed what a sponsor and advocacy organization can do when they have an established way to reach people before a shortage hits.

That distinction is especially important for an AI-generated summary. The product of a document review is a finding or a question, and the case for any next step still has to rest on the underlying evidence. The same discipline applies to registry data. A team proposing a change in trial recruitment or design would have to show where the observations came from, whom they represent and why they are relevant to the proposed study.

For sponsors deciding where to try the software, Enveda’s project gives a starting point that can be evaluated against familiar work. A team can choose a defined set of documents, agree on which findings are actionable, and compare review time and errors while recording who resolves each issue. It can then ask how the approach behaves when document quality or format changes. That evidence would help decide where an assistant is useful in another quality system.